ENDPOINTS

Vera posts positive Phase 3 rare kidney disease data, but crowded market looms

Vera Therapeutics’ rare kidney disease candidate atacicept appears to have pulled off an unusual trick: being more effective in Phase 3 than it was in Phase 2. In the pivotal ORIGIN 3 trial in the ...

Jun 2, 2025 - 11:34
 0
Vera posts positive Phase 3 rare kidney disease data, but crowded market looms
Vera Therapeutics’ rare kidney disease candidate atacicept appears to have pulled off an unusual trick: being more effective in Phase 3 than it was in Phase 2. In the pivotal ORIGIN 3 trial in the ...
Read More

Tags:

Previous Article

Daily briefing: The sweet smell of outer space

Next Article

Blueair Classic Pro CP7i air purifier review: A gentle giant with germ-busting p...

Related Posts

Regeneron makes $80M obesity deal with Hansoh

Regeneron makes $80M obesity deal with Hansoh

Jun 2, 2025  0

#ASCO25: BioNTech presents impressive early data for PD-L1xVEGF in mesothelioma

#ASCO25: BioNTech presents impressive early data for PD...

Jun 3, 2025  0

Trump axes Moderna bird flu pacts worth more than $750M

Trump axes Moderna bird flu pacts worth more than $750M

May 28, 2025  0